Related Experiment Video
Updated: Feb 26, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
[Lifelong antipsychotics? A qualitative analysis of questions about phasing out]
Background:
Many antipsychotic users at some point want to stop. They mention side effects, functioning and experiencing no benefits.
Aim:
To explore questions antipsychotic users and their relatives have about stopping or tapering antipsychotics.
Method:
Data were used from a publicly available anonymous Q&A in which experts answered questions about mental health. Questions about stopping or tapering antipsychotics asked by antipsychotics users and their relatives were analysed using an inductive content analysis.
Results:
In total 3000 questions were screened, where 426 were about antipsychotics and 194 were about stopping or tapering. The most common question was whether it was sensible to stop. Questions focused on how fast to taper, about the minimum dose, where to find support and when withdrawal symptoms or side effects would subside. Motivations were side effects, difficulties in functioning and experiencing no benefits. Barriers were lack of support and return of symptoms. Facilitators were support from others and experiencing a relief from side effects and/or symptoms.
Conclusion:
Antipsychotic users and their relatives are left with many questions about stopping. These questions reveal attitudes, preferences and concerns that are important to address when discussing antipsychotic treatment.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Therapy
Antianxiety Medications
Pharmacodynamics in Geriatric Patients: Effects of Age
Preclinical Development: Overview
Drug Dosing: Geriatric Patients

